Jeffrey S. Martini - 05 Feb 2026 Form 4 Insider Report for PALVELLA THERAPEUTICS, INC. (PVLA)

Role: Chief Scientific Officer
Signature: /s/ Kathleen A. McGowan, Attorney-in-Fact
Issuer symbol: PVLA
Transactions as of: 05 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Feb 2026, 16:08:41 UTC
Previous filing: 10 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Martini Jeffrey S	Chief Scientific Officer	C/O PALVELLA THERAPEUTICS, INC., 353 W. LANCASTER AVENUE, SUITE 200, WAYNE	/s/ Kathleen A. McGowan, Attorney-in-Fact	09 Feb 2026	0001914560

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PVLA	Stock Option (Right to Buy)	Award	$0	+64,318		$0.000000	64,318	05 Feb 2026	Common Stock	64,318	$76.43	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.